Novartis India has agreed to pay Rs12.5bn ($132m) to acquire the Minipres and Minipress trademarks in India, along with associated intellectual property rights, from Pfizer and Pfizer Products. The deal adds an established hypertension brand to Novartis' cardiovascular range and was cleared by Novartis India's board, after which the company signed an asset purchase agreement and trademark assignment deeds with the two Pfizer entities. The transaction covers trademarks registered in India, with signing and closing occurring simultaneously, and is not a related-party transaction. The agreement coincides with Pfizer's withdrawal of Minipress XL in India, as Pfizer will stop marketing, distributing, and selling the product from 7 September after Pfizer USA decided to end its manufacture. Minipress XL, containing prazosin, is used mainly to treat hypertension and manage urinary symptoms linked to benign prostatic hyperplasia, giving Novartis India a brand spanning both cardiovascular treatment and BPH management. Citing IQVIA data, Novartis India said Minipress XL recorded revenue of Rs2.28bn in the 12 months to July 2026, growing at a compound annual growth rate of 6.3% over the past four years, below the 9% recorded by the wider category. The payment is substantial for Novartis India, which has been building its portfolio through selective brand purchases, and comes after private equity company ChrysCapital agreed in December 2025 to acquire a controlling stake in Novartis India.
Pfizer IncPfizer sells Minipres/Minipress India trademarks for $132m while exiting the product, monetizing the asset.
